Pharmacokinetics, metabolism and excretion of [14C]-lanicemine (AZD6765), a novel low-trapping N-methyl-d-aspartic acid receptor channel blocker, in healthy subjects

Xenobiotica

Volumn 45, Issue 3, 2015, Pages 244-255

  Guo, Jian ^a   Zhou, Diansong ^a   Grimm, Scott W ^a   Bui, Khanh H ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

(1S) 1 phenyl 2 (pyridin 2 yl)ethanamine; Antidepressant; Major depressive disorder

Indexed keywords

GLUCURONIDE; LANICEMINE; CARBON; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENETHYLAMINE DERIVATIVE; PYRIDINE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HALF LIFE; DRUG INFUSION; DRUG METABOLISM; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HYDROXYLATION; MAJOR DEPRESSION; MALE; METABOLITE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMA; PLASMA CLEARANCE; RADIOACTIVITY; SINGLE DRUG DOSE; URINALYSIS; URINARY EXCRETION; ADULT; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CLINICAL TRIAL; FECES; INTRAVENOUS DRUG ADMINISTRATION; MASS SPECTROMETRY; METABOLISM; METABOLOME; MIDDLE AGED; TIME;

ADMINISTRATION, INTRAVENOUS; ADULT; CARBON RADIOISOTOPES; FECES; HEALTHY VOLUNTEERS; HUMANS; MALE; MASS SPECTROMETRY; METABOLOME; MIDDLE AGED; PHENETHYLAMINES; PYRIDINES; RECEPTORS, N-METHYL-D-ASPARTATE; TIME FACTORS;

EID: 84923861708     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2014.966175     Document Type: Article

References (27)

1. Altamura C, Maes M, Dai J, Meltzer HY. (1995). Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Eur Neuropsychopharmacol 5:71-5.
2. Altamura CA, Mauri MC, Ferrara A, et al. (1993). Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry 150: 1731-3.
3. Autry AE, Adachi M, Nosyreva E, et al. (2011). NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475:91-5.
4. Burrows GD, Maguire KP, Norman TR. (1998). Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. J Clin Psychiatry 59:4-7.
5. Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-5.
6. Dolgin E. (2013). Rapid antidepressant effects of ketamine ignite drug discovery. Nat Med 19:8.
7. Hajos M, Fleishaker JC, Filipiak-Reisner JK, et al. (2004). The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev 10:23-44.
8. Hamilton RA, Garnett WR, Kline BJ. (1981). Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408-13.
9. Jutkiewicz EM. (2006). The antidepressant-like effects of delta-opioid receptor agonists. Mol Interv 6:162-9.
10. Katz MM, Tekell JL, Bowden CL, et al. (2004). Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology 29:566-79.
11. Krystal JH, Karper LP, Seibyl JP, et al. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214.
12. Kucukibrahimoglu E, Saygin MZ, Caliskan M, et al. (2009). The change in plasma GABA, glutamine and glutamate levels in fluoxetine-or S-citalopram-treated female patients with major depression. Eur J Clin Pharmacol 65:571-7.
13. Machado-Vieira R, Salvadore G, Diazgranados N, Zarate Jr CA. (2009). Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther 123:143-50.
14. Machado-Vieira R, Salvadore G, Luckenbaugh DA, et al. (2008). Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry 69: 946-58.
15. Maes M, Verkerk R, Vandoolaeghe E, et al. (1998). Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand 97:302-8.
16. Mathews DC, Henter ID, Zarate CA. (2012). Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs 72:1313-33.
17. Mauri MC, Ferrara A, Boscati L, et al. (1998). Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology 37:124-9.
18. Mitani H, Shirayama Y, Yamada T, et al. (2006). Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry 30: 1155-8.
19. Papakostas GI, Stahl SM, Krishen A, et al. (2008). Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. J Clin Psychiatry 69: 1287-92.
20. Rush AJ, Trivedi MH, Wisniewski SR, et al. (2006). Acute and longerterm outcomes in depressed outpatients requiring one or several treatment steps: a STAR,D report. Am J Psychiatry 163:1905-17.
21. Sanacora G, Zarate CA, Krystal JH, Manji HK. (2008). Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 7:426-37.
22. Sanacora G, Smith MA, Pathak S, et al. (2013). Lanicemine: a lowtrapping NMDA channel blocker producessustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry 15:1-8.
23. Sanacora G, Johnson M, Khan A, et al. (2014). Adjunctive lanicemine (AZD6765) in patients with major depressive disorder and a history of inadequate response to antidepressants: primary results from a randomized, placebo-controlled study (PURSUIT). 2014 NCDEU Annual Meeting (Poster #54).
24. Stahl SM, Nierenberg AA, Gorman JM. (2001). Evidence of early onset of antidepressant effect in randomized controlled trials. J Clin Psychiatry 62:17-23; discussion 37-40.
25. Thompson C. (2002). Onset of action of antidepressants: results of different analyses. Hum Psychopharmacol 17:S27-32.
26. Zarate Jr CA, Mathews D, Ibrahim L, et al. (2013). A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry 74:257-64.
27. Zenser TV, Lakshmi VM, Davis BB. (1999). Human and Escherichia coli beta-glucuronidase hydrolysis of glucuronide conjugates of benzidine and 4-aminobiphenyl, and their hydroxy metabolites. Drug Metab Dispos 27:1064-7.